Skip to content

Multicenter Retrospective Analysis About the Clinical Characteristics of Korean Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients

Multicenter Retrospective Analysis About the Clinical Characteristics of Korean Patients With PNH

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01224483
Enrollment
350
Registered
2010-10-20
Start date
2010-08-31
Completion date
2010-12-31
Last updated
2010-10-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hemoglobinuria, Paroxysmal

Brief summary

Paroxysmal nocturnal hemoglobinuria (PNH) is a hematopoietic stem cell disorder in which unregulated activation of the complement system leads to significant ischemic morbidities with shortened lifespan. Life-threatening thromboembolism (TE) is the most feared complication of PNH, accounting for up to 45% of patient deaths. It is estimated that 40% of PNH patients experience a clinically evident TE and 60% of patients without clinically diagnosed TE demonstrate TE by high-sensitivity MRI, indicating the ongoing thrombotic risk in most patients with PNH. Much of these data come from PNH patients from European descent. To understand the impact of TE in patients with PNH from non-European regions, we performed this study to evaluate the clinical characteristics of Korean patients with PNH.

Detailed description

To evaluate the clinical characteristics in Korean PNH patients

Interventions

None listed

Sponsors

Samsung Medical Center
Lead SponsorOTHER

Study design

Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
1 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Diagnosis confirmed by Ham's test or Flow cytometry Patients have any Flow cytometry data

Exclusion criteria

* Patients have no Flow cytometry data

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 15, 2026